MetaVia
MTVAMetaVia Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel pharmaceuticals for cardiometabolic diseases.
$10.28M-26.9%
Table of contents
Earnings
Next report
Aug 6, 2026 (In 3 weeks)EPS estimate-$0.85
Competitors
By market cap
By revenue growth
Profile
MetaVia Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel pharmaceuticals for cardiometabolic diseases. The company's primary value proposition centers on its pipeline of therapeutic candidates targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Its lead programs utilize GPR119 and GLP-1/glucagon receptor dual agonism to address hepatic and metabolic pathways.
Competitive position
MetaVia is a clinical-stage developer focused on first-in-class and differentiated dual-activity mechanisms for metabolic liver diseases.
GeographiesUnited States
Customer segmentsStrategic partners, Healthcare providers
Business modelR&D-stage biotechnology, Licensing and IP
SuppliersContract Research Organizations (CROs), Clinical trial sites, Raw material suppliers for drug synthesis
CustomersLarge pharmaceutical companies for potential licensing, Specialized healthcare providers, Patients with metabolic syndrome
CountryUnited States of America
Listed2016
Employees8.0
CEOHyung Heon Kim
SectorHealthcare
IndustryBiotechnology
Websitemetaviatx.com
FilingsSEC EDGAR
Questions, answered.
- What is MetaVia's market cap?
- MetaVia (MTVA) has a market capitalization of $10.3M and trades on XNAS.
- Who are MetaVia's competitors?
- MetaVia's key competitors include Viking Therapeutics, Madrigal Pharmaceuticals, Eli Lilly and Company, and others. These companies compete in similar markets and product categories.
- Who does MetaVia partner with?
- MetaVia's notable partners include Dong-A ST.
- Where is MetaVia headquartered?
- MetaVia is headquartered in United States of America and employs approximately 8 people. It has been publicly traded since 2016.